Tesamorelin 20mg

Description

Tesamorelin is a GHRH analog with human trial data and approved indication-specific use, most prominently in HIV-associated abdominal adiposity contexts.

What it is

Tesamorelin is a GHRH analog with clinical-trial evidence and indication-specific approved use, especially in HIV-associated abdominal adiposity contexts.

Mechanism snapshot

• Stimulates endogenous GH release via GHRH receptor activation.
• Investigated for visceral-fat reduction and metabolic-parameter changes.
• Evaluated through longer-horizon safety extensions and responder analyses.

Research programs

• Randomized placebo-controlled HIV-associated adiposity trials.
• Metabolic profile and body-composition endpoint tracking.
• Predictor-of-response analyses in treated cohorts.

Limitations

• Clinical interpretation should remain bounded to studied populations.
• Response magnitude varies across patient subgroups.
• Long-term benefit-risk interpretation requires indication context.

Selected references

• Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension - PubMed 2010
• Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation - PubMed 2008
• Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat - PubMed 2015
• TH9507 in Patients With HIV-Associated Lipodystrophy (NCT00123253) - ClinicalTrials.gov Status snapshot
• EGRIFTA (tesamorelin) U.S. Prescribing Information - FDA Label 2025

Ordering

Add this item to your cart, submit your shipping details at checkout, and wait for your order confirmation. Interac e-Transfer instructions are sent after the order request is received.